tbuckley/cabot-search huggingface dataset:
Abstract 14542: High-Sensitivity Troponin T is a Prognostic Marker in Cardiac Sarcoidosis
Authors: Riina Kandolin, Jukka Lehtonen, Markku Kupari
Journal: Circulation (2013)

Background: Cardiac sarcoidosis (CS) is a progressive inflammatory myocardial disease that often leads to left ventricular dysfunction. There are currently no markers of disease activity that would...
Mucin Histochemistry of Human Gallbladder: Changes in Adenocarcinoma, Cystic Fibrosis, and Cholecystitis&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: J. R. Esterly, M.D., S. S. Spicer, M.D.
Journal: JNCI Journal of the National Cancer Institute (1968)

The type and distribution of epithelial mucins in the gallbladder were investigated with a variety of histochemical techniques. Adenocarcinoma, cystic fibrosis, mucocele, and cholecystitis were among the lesions studied. The apical cytoplasm in the surface epithelium and the surface mucous layer of apparently normal gallbladders showed staining indicative of sulfomucin. The increased secretions in these sites in patients with cystic fibrosis, mucocele, and inflammation stained similarly. The increased numbers of goblet cells in the surface epithelium under pathologic conditions showed staining suggestive of carboxymucin. Cells in the mucous glands of the lamina propria, particularly in the neck area, appeared to secrete several mucosubstances with the reactivity of carboxymucin, or neutral mucin. Occasional cells contained a mixture of these substances. In contrast, carboxymucin was the predominant acid mucosaccharide identified in adenocarcinoma of the gallbladder. Staining indicative of sulfomucins and carboxymucins was most clearly delineated with a high iron diamine-alcian blue sequence. Satisfactory reactions were obtained with several routine fixatives, but differentiation of sulfomucins and carboxymucins was most easily appreciated in formalin-fixed tissues. This fixative also appeared morphologically to enhance the preservation of intracellular mucin and mast cell granules.
Abstract 10179: Myocardial T1 in Nonischemic Dilated Cardiomyopathy is Related to Circulating Procollagen Type 1 Carboxyterminal Peptide and Predicts Reverse Remodeling by Spironolactone Therapy
Authors: William Bradham, Susan P Bell, Holly Smith, Douglas Adkisson, Mark A Lawson, Henry Ooi, Douglas B Sawyer, Marvin W Kronenberg
Journal: Circulation (2013)

Introduction: Pathologic collagen remodeling and fibrosis are prominent features of nonischemic dilated cardiomyopathy (NIDCM) and heart failure (HF). Circulating levels of collagen markers, such a...
Effect of asthma control and quality of life on the use of alternative medicine
Authors: Ela Erdem, Yasemin Gokdemir, Refika Ersu, Fazilet Karakoc, Bulent Karadag
Journal: European Respiratory Journal (2012)

Asthma is the most common chronic lower respiratory tract disease of childhood. It may affect the quality of life of the child and the parents. Nowadays, use of alternative treatment (AT) methods are increased in treatment of asthma and/or relief of symptoms. But there are limited studies showing the efficiency of AT and evaluating the asssociation between asthma control and AT usage. We investigated the prevalance of AT usage and effect of AT usage on asthma control and quality of life in patients with asthma.  Study included 80 patients with asthma followed up in Pediatric Pulmonology Department. “Pediatric Asthma Quality of Life Questionnaire” (PAQLQ) was used to evaluate the quality of life; “Asthma Control Test” (ACT) and “Asthma Control Questionnaire” (ACQ) were used to measure asthma control.  Mean age of the patients were 9.2±3.2. 63.8% of the patients used at least one method of AT in their life besides the recommended treatment. The most commonly used methods were; carob molasses (36.3%), herbals (%26.3), quails (22.5%), honey in black radish (15%), chestnut honey (11.3%) and bee pollen (5%), respectively. Of whole, 59.6% of the patients got benefit from AT. Mean score of PAQLQ was 5.9±1.0. Parents with younger kids were found to use more AT methods (p=0.002). There were no association between the use of AT and time of the diagnosis of asthma, time of anti-inflammatory drugs usage, PAQLQ, ACT and ACQ (p>0.05).  In conclusion, AT is frequently used in our patients. We found that there was no effect of level of asthma control and quality of life on preferring AT.
Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
Authors: R M Navari, S Madajewicz, N Anderson, N S Tchekmedyian, W Whaley, H Garewal, T M Beck, A Y Chang, B Greenberg, K C Caldwell
Journal: Journal of Clinical Oncology (1995)

PURPOSE To investigate the efficacy and safety of oral ondansetron in the control of cisplatin-induced delayed emesis in patients who do not require rescue antiemetic therapy for acute emesis. PATIENTS AND METHODS Five hundred thirty-eight chemotherapy-naive patients who received cisplatin chemotherapy (&gt; or = 70 mg/m2), and who were not rescued for acute emesis, were eligible to be randomized to receive one of the three oral regimens to control delayed emesis. Group I received placebo on days 2 to 6; group II received ondansetron 8 mg twice daily on days 2 and 3 and placebo on days 4 to 6; group III received ondansetron 8 mg twice daily on days 2 to 6. All patients received intravenous ondansetron (0.15 mg/kg every 4 hours for three doses) for the control of acute emesis on day 1. The number of emetic episodes on days 2 and 3 combined (days 2/3, when incidence and severity of delayed emesis were expected to be greatest) was considered the primary measure of efficacy. RESULTS Patients who received odansetron had significantly fewer emetic episodes on days 2/3, 4, and 5 than those who received placebo (P &lt; or = .002 on each day). Additionally, significantly more patients who received ondansetron had a complete plus major response (C+MR; &lt; or = two two emetic episodes) than those who received placebo on days 2/3 (56% v 37%, P = .001), 4 (94% v 85%, P = .005), and 5 (98% v 88%, P = .006). Patients who received ondansetron had significantly less nausea on day 2/3 when day-1 nausea was used as the baseline score (P = .025). Patients who received ondansetron also had significantly less nausea on day 4 (P = .042) and the results approached significance on day 5 (P = .066). CONCLUSION Oral ondansetron had a significant effect in the control of cisplatin-induced delayed emesis and nausea in patients who had not required rescue antiemetics during the acute emesis period. The control of delayed nausea and vomiting was most notable in the immediate 2 days following cisplatin administration, with the clinical difference narrowing between the two treatment arms on subsequent days.
제3차 대한간학회 춘계학술대회 초록집 : 포스터연제 토의 ; 간농양으로 오인된 de novo 간세포암 1예
Authors: 이현숙 ( Lee Hyeon Sug ), 여미애 ( Yeo Mi Ae ), 이준상 ( Lee Jun Sang ), 심정원 ( Sim Jeong Won ), 이경원 ( Lee Gyeong Won ), 양익 ( Yang Ig ), 김형건 ( Kim Hyeong Geon ), 김우중 ( Kim U Jung )
Journal: Clinical and Molecular Hepatology (1997)
SF-36 quality of life questionaire evaluation in a large cohort of women with breast cancer treated with hormonotherapy
Authors: E. L. Morgenfeld, B. Rolnik, L. Cassab, D. Gercovich, F. Negro, J. C. Calarame, F. Tognelli, E. Rivarola, E. Gil Deza, F. G. Gercovich
Journal: Journal of Clinical Oncology (2007)

19657 Background: Hormonotherapy (H) is the most widely used treatment against breast cancer (BC). The aim of this study is a prospective evaluation with an enriched the SF-36 questionnaire, of the QOL of BC patients (pt) treated with H at the IOHM. Specific questions regarding menopausal symptoms and body weight were added. Methods: Between Aug 2005 and Nov 2006, all pt that were undergoing H, were requested to fill out a SF-36 self-evaluation form. The SF-36 is a multi-purpose, short-form health survey, with 36 questions about functional health and well-being. The answers were tabulated. The pre-treatment and post-treatment body weight of each pt was registered. Results: Three Hundred and Twenty-six pt were invited to participate, and all of them accepted, and signed a consent form. Characteristics of the population: Diagnosis: DCIS: 36 pt; LCIS: 5 pt; IDC 250 pt; ILC: 35 pt. All cases expressed hormonal receptors. The H was adjuvant in 254 pt (78%) mostly treated with T and palliative in 72 pt (22%) mostly treated with AI. Median age was 62 years, however 63 pt (19%) were pre-menopausal. The median time under treatment was 33 months (range 1–71 m). The pt reported: General evaluation of Quality of life: Very good or excellent: 154 pt (47%) , Good: 134 pt (41%), Poor: 34 pt (11%). Severe limitations for demanding physical activities: 43 pt (13 %). A reduction of time spent on the job: 66 pt (22%). Severe pain during the last four weeks prior to answering the questionnaire: 24 pt (8 %). Weight increase perception: 153 pt (47%). Actual increase of weight: 192 pt (60%) (Median: 4 kg). Menopausal symptoms: Daily Hot Flushes: 132 pt (40%). Vaginal discharge 110 pt (33%) Decrease of libido: 98 pt (30%), Vaginal dryness 76 pt (23%), Nightly sweats: 40 pt (12%). Sixty pt (18%) suffered from and received treatment for menopausal symptoms. Conclusions: 1) The SF-36 is a useful tool to measure the BC patients’ quality of life 2) Although in our cohort most of the patients (88,3%) rated their general QOL as “good to very good”, a third of the pt presented severe menopausal symptoms, and 18% received non hormonal medication for symptoms relief 3) Sixty percent of the pt had a median body weight gain of 4 Kg. No significant financial relationships to disclose.
Assessment of tumor suppressor gene methylation for breast cancer risk screening
Authors: D. Euhus, R. Ashfaq, D. Bu, A. M. Leitch, C. Lewis
Journal: Journal of Clinical Oncology (2006)

1004 Background: Tumor suppressor gene (TSG) methylation is frequently detected in benign proliferative breast tissue suggesting that it occurs early in breast carcinogenesis. If it can be screen-detected and is associated with breast cancer risk it could be exploited for breast cancer prevention. Methods: Nipple duct lavage (NDL) samples, obtained from 150 women selected to represent a wide range of breast cancer risk, were evaluated by quantitative methylation-specific real time PCR. High risk breasts were defined as those contralateral to a breast cancer (N = 63) and those of women with a 5-year Gail risk ≥ twice the age- and race-matched general population risk (N = 64). The prevelence of TSG methylation and marked atypia was compared for high risk and lower risk breasts using Chi-square. Data for breasts ipsilateral to a breast cancer are shown for comparison, but not included in the calculations for the high risk category. Results: Samples with adequate cellularity were obtained for 219 breasts (76%). The proportion of healthy breasts with ≥ 1% of the gene copies methylated was 13% for Cyclin D2, 19% for APC, 19% for HIN-1, 16% for RASSF1A, and 9% for RAR-beta. RAR-beta provided the best risk discrimination as 15% of high risk breasts were methylated at a level that exceeded the 95 th percentile of the lower risk breasts (0.9% of gene copies methylated, P = 0.05). For the table , methylation fractions for all five genes were summed and the threshold for classifying a breast as positive was set to the 95 th percentile of the lower risk breasts (methylation sum = 25.0%). Both methylation and marked atypia provide some discrimination between high and lower risk breasts; the combination, however, provides the best discrimination (24% marker positive for high risk versus 9% for lower risk, P = 0.02). Conclusions: TSG methylation in NDL samples is a marker of breast cancer risk that is complementary to cytology. [Table: see text] [Table: see text]
Abstract 18799: Association of Long-term Risk Factor Levels with Coronary Artery Wall Remodeling Indices: The Chicago Healthy Aging Low-RISk Magnetic Resonance Angiography (CHARISMA) Study
Authors: Donald M Lloyd-Jones, Jarett D Berry, Hongyan Ning, Kai Lin, Martha Daviglus, Kiang Liu, Debiao Li, Joseph A Walsh, James Carr
Journal: Circulation (2012)

Background: Coronary artery wall remodeling (CAR) has recently been recognized as an important feature of atherosclerosis development. Long-term associations of risk factor (RF) burden with remodeling indices have not been described. Methods: In 2009-11, we performed MR angiography in 440 randomly-selected participants (ppts) of the Chicago Healthy Aging Study, whose RFs had been measured in 1967-73. We examined association of aggregate burden of RFs with CAR indices measured by 1.5T MR imaging. Cross-sectional images of the proximal portions of the left main (LMCA, 1 slice), left anterior descending (LAD, 3 slices) and right (RCA, 3 slices) coronary arteries prescribed using coronary landmarks were acquired using a breath-hold, black-blood, ECG-gated, turbo spin echo sequence. RF burden at baseline was stratified into “Low Risk” (untreated cholesterol &lt;200 mg/dL, untreated blood pressure &lt;120/&lt;80 mm Hg, not smoking and no diabetes) and “Not Low Risk,” including all others. Individual RF associations were also examined. Results: Among 422 ppts with evaluable images, the mean age was 32±5 y at baseline and 71±5 y at follow-up; 65% were male and 84% white. By design, 154/422 (36.5%) had the Low Risk profile at baseline, but only 5.5% maintained it at follow up. The Table shows the CAR indices, stratified by Low Risk status at baseline. Mean and maximal wall thickness measures were significantly lower for ppts with Low Risk status at baseline in the LMCA and LAD, as was overall coronary wall area in the LAD. Associations were generally as expected for individual RFs and were particularly significant for baseline obesity. Conclusions: These are the first data to examine long-term associations of RF burden with indices of coronary artery wall remodeling. These associations may explain part of the mechanism of the decades-long protection against development of clinical coronary events observed in individuals with the Low Risk profile in younger adulthood.
Abnormalities of Monocyte Chemotaxis in Patients With Melanoma: Effects of Immunotherapy and Tumor Removal2
Authors: R. Snyderman, H. F. Seigler, L. Meadows
Journal: JNCI Journal of the National Cancer Institute (1977)

The chemotactic responsiveness of peripheral blood monocytes was studied before and after immunotherapy was administered to 56 patients with melanoma. Abnormal chemotaxis was found in 36 patients (64%) prior to treatment; this abnormality correlated with severity of disease and prognosis. Immunotherapy with BCG and sensitized autologous lymphocytes and X-irradiated melanoma cells or surgical removal of the neoplasm both reduced the percentage of patients with abnormal chemotactic responses. The best prognosis was found for those patients who had normal chemotaxis prior to therapy. The data support the hypothesis that abnormalities of monocyte function might render the host less likely to destroy developing neoplasms and that malignant tumors themselves might affect monocyte function.
HIV negative people should be responsible for protecting themselves
Authors: S. Macwilliam
Journal: BMJ (1996)

EDITOR,—Renee Danziger reports on moves to change the emphasis of policy on HIV prevention on the grounds, apparently, that AIDS has become “normalised,” but the evidence that she presents to justify this assertion is unconvincing.1 She points out that in the West the epidemic has not spread as rapidly as predicted; she is right, but how can this be said to show normalisation? If anything, it tends to prove the effectiveness of those elective preventive measures …
Abstract 16668: Serum Gamma Glutamyl Transferase and Risk of Coronary Artery Disease: A Causal Assessment by Mendelian Randomization
Authors: Krishna G Aragam, Wei Zhao, Omar Shah, Asif Rasheed, Megan Wolfe, Muredach Reilly, John Danesh, Daniel J Rader, Danish Saleheen, Promis study
Journal: Circulation (2013)

Background: Gamma glutamyl transferase (GGT) is a ubiquitous cell-surface enzyme that mediates oxidative stress and is elevated in persons with hepatic steatosis. Observational data have suggested ...
Effects of neoadjuvant therapy on pancreatic cancer stem cells.
Authors: Adam R. Miller, Whitney H. Horsley, George Sandusky, Melissa Stanley, Bert H. O'Neil, Safi Shahda
Journal: Journal of Clinical Oncology (2015)

292 Background: Several factors are involved in pancreatic cancer’s (PC) resistance to therapy. Cancer Stem cells (CSCs) represent a small and unique population of cancer cells, that are resistant to chemotherapy and radiotherapy and have the capability to differentiate and produce further resistant clones. Our hypothesis was that stem cell frequency would differ in treated vs. untreated pancreatic cancers. Methods: Resected FFPE PC specimens were collected under IRB- approved protocols and were separated into two group categories: cases that received neoadjuvant therapy (NA) and matched control cases with no treatment prior to surgical resection (SU). Immunostaining with CD24 and ALDH1 was performed using the DAKO FLEX SYSTEM. Each slide was scanned using the Aperio Whole Digital Imaging System. The digital scans were analyzed using the standard positive pixel algorithm for immunostains (brown positive, blue negative) that gives a percent of positive pixels in the cross section of the tissue. Care was taken to exclude false-positive staining sections of intact physiologic acinar and islet cells. Positivity data was compared between the two groups using a two-sample t-test using unequal or equal variances where an F-test deemed each appropriate. Results: Twenty cases were examined (10 NA and 10 SU). Patients in the NA arm received the following treatments (4 FOLFIRINOX, 2 nab-Paclitaxel + gemcitabine, 2 treated with concurrent gemcitabine/radiotherapy and 2 patients’ details are not available). Using two-sample t-test analysis, we found a statistically significant difference of median expression (percent positive pixels) of CD24 (20.5% vs. 66.9% expression, P &lt;0.01,) and ALDH1 (41.5% vs. 60.5%, P= 0.04) between NA vs. SU respectively. This small study demonstrates lower expression of CSCs markers in patients receiving NA therapy in comparison to SU treated patients, indicating an effect from neoadjuvant therapy on CSCs. Conclusions: This is the first analysis of CSCs markers in patients with PC receiving NA therapy compared to surgery. In this small group, CSCs markers reflecting CSCs numbers in patients’ tumors were lower in the group receiving NA therapy prior to surgery; suggesting that CSCs may in fact be sensitive to standard chemotherapy.
Phosphorylated α-Synuclein in Parkinson’s Disease
Authors: Yu Wang, Min Shi, Kathryn A. Chung, Cyrus P. Zabetian, James B. Leverenz, Daniela Berg, Karin Srulijes, John Q. Trojanowski, Virginia M.-Y. Lee, Andrew D. Siderowf, Howard Hurtig, Irene Litvan, Mya C. Schiess, Elaine R. Peskind, Masami Masuda, Masato Hasegawa, Xiangmin Lin, Catherine Pan, Douglas Galasko, David S. Goldstein, Poul Henning Jensen, Hui Yang, Kevin C. Cain, Jing Zhang
Journal: Science Translational Medicine (2012)

An assay for detecting phosphorylated α-synuclein in CSF may help to diagnose Parkinson’s disease and determine disease severity.
BCRA 1 testing guidelines for high-risk patients.
Authors: S Sorscher, P Levonian
Journal: Journal of Clinical Oncology (1997)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1997.15.4.1711 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9213589 BCRA 1 testing guidelines for high-risk patients. S SorscherxS SorscherSearch for articles by this author , P LevonianxP LevonianSearch for articles by this author https://doi.org/10.1200/JCO.1997.15.4.1711 PDF "BCRA 1 testing guidelines for high-risk patients.." Journal of Clinical Oncology, 15(4), p. 1711© 1997 by American Society of Clinical Oncology
Abstract 13860: An Unique Animal Model of Spontaneous Atherothrombotic Occlusion due to Plaque Erosion at Femoral Arteries of Atherosclerotic Rabbits Infused with Angiotensin II
Authors: Yoshibumi Antoku, Tetsuya Matoba, Takeo Yufu, Kaku Nakano, Kensuke Egashira
Journal: Circulation (2012)

Background:  Plaque erosion is known to be a major cause of coronary atherothrombosis that leads to acute coronary syndrome. However, the mechanism of plaque erosion remains poorly understood, because of the lack of appropriate animal models. Here we report a first animal model of plaque erosion with spontaneous atherothrombotic occlusion.   Methods and Results:  The occurrence of atherothrombosis was examined in femoral arteries of Japanese white rabbits fed with high cholesterol diet by high-resolution ultrasonography (Vevo 2100, VISUALSONICS Inc.) (Fig. A). Balloon injury of femoral arteries caused neointima formation that consist from de-differentiated (αSMA+/SM1+/SM2-) smooth muscle cells (SMCs), but did not result in atherothrombosis. Importantly, the addition of angiotensin II infusion caused spontaneous atherothrombotic occlusion of the injured arteries at median 5.5 weeks (6/6 animals, Fig. B). After the occurrence of acute thrombotic occlusion, the presence of thrombosis was confirmed by angiographic and histopathologic examination. Histochemical analysis in the atherothrombotic sites revealed; 1) no severe stenosis (% stenosis: 49±7), 2) no plaque rupture or lipid core, and, 3) no PECAM1-positive endothelial layer. Interestingly, there were especially immature SMCs (αSMA+/SM1-/SM2-) with tissue factor expression at the neointima-thrombus interface (NTI) (Fig. C). Oral treatment with aspirin (20 mg/day) and dabigatran (10 mg/kg/day) prevented atherothrombotic occlusion (0/5 animals, P   Conclusion:  We established for the first time an appropriate and valid animal model of spontaneous atherothromobotic occlusion due to plaque erosion in rabbits, which mimicked the pathological features of plaque erosion seen in human coronary arteries. This model may provide a clue to a mechanistic understanding of plaque erosion and to the development of drugs that prevent or delay plaque erosion and subsequent atherothrombosis.
The Emerging Zika Pandemic
Authors: Daniel R. Lucey, Lawrence O. Gostin
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal